A University of Central Florida researcher is part of a new study showing that artificial intelligence can be nearly as accurate as a physician in diagnosing COVID-19 in the lungs.

The study, recently published in Nature Communications, shows the new technique can also overcome some of the challenges of current testing.

Close2U, an electronic device application, has been developed by researchers at the Complutense University (UCM) and the University of Zaragoza (UZA) to monitor cancer patients' physical and mental health using gamification.

Users answer a series of daily questions about their mood and where they are experiencing pain. In return, the app rewards them in the form of advice or songs, resources intended to increase their motivation.

Researchers at the University of East Anglia have been putting virtual reality rehabilitation for stroke survivors to the test. They have created a new gaming platform which uses low cost videogame technology to improve the lives of stroke patients suffering from complex neurological syndromes caused by their stroke. And they have been working with stroke survivors and their carers to see how they get on with using the new technology.

Hailed for its ability to erase distance between health care providers in cities and patients in rural areas, telehealth has ironically enabled medical care to continue in a time when we all must keep our distance.

Across the country, telehealth use has spiked as providers offer virtual patient visits to ensure medical needs are met while minimizing COVID-19 exposure. Regulatory agencies have loosened some restrictions on telehealth during this crisis, and more and more payers have begun to reimburse for it as they would for any other medical service.

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19. The findings are reported today in Science.

In the experiments, the lead antiviral candidate, named LCB1, rivaled the best-known SARS-CoV-2 neutralizing antibodies in its protective actions. LCB1 is currently being evaluated in rodents.

Robust and widespread antibody testing has emerged as a key strategy in the fight against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. However current testing methods are too inaccurate or too expensive to be feasible on a global scale. But now, scientists at the Okinawa Institute of Science and Technology Graduate University (OIST) have developed a rapid, reliable and low-cost antibody test.

Contract tracing apps used to reduce the spread of COVID-19 are unlikely to be effective without proper uptake and support from concurrent control measures, finds a new study by UCL researchers.

The systematic review, published in Lancet Digital Health, shows that evidence around the effectiveness of automated contact tracing systems is currently very limited, and